benzyl N-[(2S)-1-oxo-6-(prop-2-enylamino)-1-(4-pyridin-2-ylpiperazin-1-yl)hexan-2-yl]carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: benzyl N-[(2S)-1-oxo-6-(prop-2-enylamino)-1-(4-pyridin-2-ylpiperazin-1-yl)hexan-2-yl]carbamate
• 化学式: C₂₆H₃₅N₅O₃
• 分子量: 465.6
• InChiKey: UVJXNISHHCAECN-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  34
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  86.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE TRANSGLUTAMINASE TG2, COMPOSITIONS PHARMACEUTIQUES, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：DOMINGUEZ CELIA

  公开号：WO2014047288A2

  公开（公告）日：2014-03-27

  Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.